Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound a, in human bone marrow stromal cells

Endocrinology

Volumn 152, Issue 1, 2011, Pages 103-112

  Rauner, Martina ^a   Goettsch, Claudia ^a   Stein, Nicola ^a   Thiele, Sylvia ^a   Bornhaeuser, Martin ^b,c   De Bosscher, Karolien ^d   Haegeman, Guy ^d   Tuckermann, Jan ^e   Hofbauer, Lorenz C ^a,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Division of Hematology   (United States)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^d GHENT UNIVERSITY   (Belgium)

^e FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; BUDESONIDE; COMPOUND A; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; BONE MINERALIZATION; CELL PROLIFERATION; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ACETATES; ADULT; APOPTOSIS; BONE MARROW CELLS; CELLS, CULTURED; COCULTURE TECHNIQUES; ETHYLAMINES; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; OSTEOCLASTS; OSTEOGENESIS; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78650850288     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0456     Document Type: Article

References (27)

1. Hofbauer LC, Rauner M 2009 Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol 23: 1525-1531
2. Zhou H, Mak W, Kalak R, Street J, Fong-Yee C, Zheng Y, Dunstan CR, Seibel MJ 2009 Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 136:427-436
3. Eijken M, Koedam M, van Driel M, Buurman CJ, Pols HA, van Leeuwen JP 2006 The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol Cell Endocrinol 248:87-93
4. Hamidouche Z, Hay E, Vaudin P, Charbord P, Schüle R, Marie PJ, Fromigue O 2008 FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt//3-catenin signaling-dependent Runx2 expression. FASEB J 22:3813-3822
5. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocor-ticoid-induced osteoporosis: pathophysiology and therapy. Osteo-poros Int 18:1319-1328
6. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253-1263
7. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R 2010 Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872-875
8. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, Kostenuik PJ, Erben RG 2009 Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 60:1427-1437
9. Schacke H, Berger M, Rehwinkel H, Asadullah K 2007 Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275:109-117
10. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN 2003 A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 17: 860-869
11. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K 2004 Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101:227-232
12. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G 2005 A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 102:15827-15832
13. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, Van Calenbergh S, Muller-Ladner U, Vander Cruyssen B, Verbruggen G, Haegeman G, Elewaut D 2008 A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 180:2608-2615
14. Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch UK, van den Brandt J, Lühder F, Reichardt HM 2009 Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLo S One 4:e8202
15. Ugarte F, Ryser M, Thieme S, Fierro FA, Navratiel K, Bornhauser M, Brenner S 2009 Notch signaling enhances osteogenic differentiation while inhibiting adipogenesis in primary human bone marrow stromal cells. Exp Hematol 37:867-875.e861
16. Rauner M, Sipos W, Goettsch C, Wutzl A, Foisner R, Pietschmann P, Hofbauer LC 2009 Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogen-esis. J Bone Miner Res 24:78-86
17. van Loo G, Sze M, Bougarne N, Praet J, McGuire C, Ullrich A, Haegeman G, Prinz M, Beyaert R, De Bosscher K 2010 Antiinflam-matory properties of a plant-derived nonsteroidal, dissociated glu-cocorticoid receptor modulator in experimental autoimmune en-cephalomyelitis. Mol Endocrinol 24:310-322
18. Owen HC, Miner JN, Ahmed SF, Farquharson C 2007 The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol 264:164-170
19. Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP 2003 Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol 85:457-467
20. Gossye V, Elewaut D, Van Beneden K, Dewint P, Haegeman G, De Bosscher K 2010 Aplant-derived glucocorticoidreceptor modulator attenuates inflammation without provoking ligand-induced resistance. Ann Rheum Dis 69:291-296
21. Zhang W, Yang N, Shi XM 2008 Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper (GILZ). J Biol Chem 283:4723-4729
22. Chang JK, Li CJ, Liao HJ, Wang CK, Wang GJ, Ho ML 2009 Anti-inflammatory drugs suppress proliferation and induce ap-optosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology 258:148-156
23. Kogianni G, Mann V, Ebetino F, Nuttall M, Nijweide P, Simpson H, Noble B 2004 Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 75:2879-2895
24. Nuutinen U, Ropponen A, Suoranta S, Eeva J, Eray M, Pellinen R, Wahlfors J, Pelkonen J 2009 Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase ki-nase-3. Leuk Res 33:1714-1717
25. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glu-cocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
26. Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S 2008 Dexameth-asone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 103:335-345
27. Humphrey EL, Williams JH, Davie MW, Marshall MJ 2006 Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38:652-661